Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04269707 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Intravenous Ferric Carboxymaltose in Pediatric Patients With Iron Deficiency Anemia and Unsatisfactory Response Oral Iron Under Study Protocol 1VIT17044
A Phase 3 study of Iron Deficiency Anemia, sponsored by American Regent.
- Completed
- Registry status
- Phase 3
- Development phase
- 7
- Enrollment target
- 2
- Study locations
NCT04269707: Completed Phase 3 study of Iron Deficiency Anemia, sponsored by American Regent.
NCT04269707 is a Phase 3 study of Iron Deficiency Anemia that has completed, run by American Regent. The registered enrollment target is 7 participants, below the 193-participant average among 24 other Iron Deficiency Anemia trials with a reported enrollment target (96% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04269707, a Phase 3 study of Iron Deficiency Anemia, has completed, sponsored by American Regent.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 7 participants
- Enrollment target
- 2
- Study locations
Study Summary
Evaluating the Efficacy and Safety of Intravenous Ferric Carboxymaltose in Pediatric Patients with Iron Deficiency Anemia and an Unsatisfactory Response to Oral Iron under Study Protocol 1VIT17044
Primary Outcome
The change in hemoglobin from Baseline to Day 35 was assessed using paired t-tests (two-sided test, α = 0.05). Baseline hemoglobin was defined as the last hemoglobin obtained before the first dose.
Conditions Studied
Interventions
- DRUG Ferric carboxymaltose
Study Locations (2)
Florida
- Miami Clinical Research - Miami
- South Florida Research Phase I-IV - Miami Springs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2019-11-19 |
| Est. Completion | 2021-01-29 |
| Phase | Phase 3 |
What the finished NCT04269707 record still lists
NCT04269707 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 193-participant average among 24 other Iron Deficiency Anemia trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Iron Deficiency Anemia appearing as the primary indexed condition, and to 1 intervention - of which Ferric carboxymaltose is the first listed.
NCT04269707 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT04269707 about?
NCT04269707 is a clinical study titled "Efficacy and Safety of Intravenous Ferric Carboxymaltose in Pediatric Patients With Iron Deficiency Anemia and Unsatisfactory Response Oral Iron Under Study Protocol 1VIT17044". Evaluating the Efficacy and Safety of Intravenous Ferric Carboxymaltose in Pediatric Patients with Iron Deficiency Anemia and an Unsatisfactory Response to Oral Iron under Study Protocol 1VIT17044
What is the current status of trial NCT04269707?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 7 participants. The study started on 2019-11-19. Estimated completion is 2021-01-29.
What conditions does trial NCT04269707 study?
This clinical trial studies the following conditions: Iron Deficiency Anemia.
What interventions are being tested in trial NCT04269707?
The interventions under investigation include: Ferric carboxymaltose (DRUG).
Who is sponsoring clinical trial NCT04269707?
This trial is sponsored by American Regent, which has 34 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04269707 being conducted?
This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Iron Deficiency Anemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04269707's enrollment target sits among peer trials
7 24th of 24 higher than 1 of 24 other Iron Deficiency Anemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Iron Deficiency Anemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient
RECRUITING · Phase 3
-
A Study to Evaluate Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects
RECRUITING · Phase 3
-
Intravenous Versus Oral Iron for Treating Iron-Deficiency Anemia in Pregnancy
RECRUITING · Phase 3
-
An Extension Trial to Assess the Safety of Re-dosing of Iron Isomaltoside/Ferric Derisomaltose (Monofer®/Monoferric®)
COMPLETED · Phase 3
-
Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia
COMPLETED · Phase 3
-
Multicenter Randomized Active-controlled Study to Investigate Efficacy & Safety of IV FCM in Pediatric Patients With IDA
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI